{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/RVMDW/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-23T07:59:11.386Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":6688,"canonical_name":"Revolution Medicines, Inc.","cik":"0001628171","uei":null,"lei":null,"duns":null,"ticker":"RVMDW"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":73,"clinical":5},"count":78,"timeline":[{"ts":"2026-09-11","kind":"sec.form144","reporter":"STEPHEN KELSEY","title":"Officer","shares":92531,"usd_value":18816179,"security_title":"Common","approx_sale_date":"2026-09-11","accession_number":"0001950047-26-009354","importance":43.76323577},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Revolution Medicines, Inc. — 2026-07-01","url_slug":"/sec/cik-0001628171/4/0001610717-26-000311","accession_number":"0001610717-26-000311","importance":30},{"ts":"2026-06-29","kind":"sec.form144","reporter":"SUSHIL PATEL","title":"Director","shares":5580,"usd_value":1016006,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001950047-26-006611","importance":40.20320128},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Patel Sushil","title":null,"shares":1100,"price_per_share":185.8991,"usd_value":204489,"security_title":"Common Stock","importance":35.20448901},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Patel Sushil","title":null,"shares":881,"price_per_share":192.6139,"usd_value":169693,"security_title":"Common Stock","importance":35.1696928459},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Patel Sushil","title":null,"shares":900,"price_per_share":184.5869,"usd_value":166128,"security_title":"Common Stock","importance":35.16612821},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Patel Sushil","title":null,"shares":858,"price_per_share":186.9157,"usd_value":160374,"security_title":"Common Stock","importance":35.1603736706},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Patel Sushil","title":null,"shares":600,"price_per_share":190.545,"usd_value":114327,"security_title":"Common Stock","importance":35.114327},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Patel Sushil","title":null,"shares":541,"price_per_share":191.8661,"usd_value":103800,"security_title":"Common Stock","importance":35.1037995601},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Patel Sushil","title":null,"shares":300,"price_per_share":187.8267,"usd_value":56348,"security_title":"Common Stock","importance":35.05634801},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Patel Sushil","title":null,"shares":300,"price_per_share":183.1733,"usd_value":54952,"security_title":"Common Stock","importance":35.05495199},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Patel Sushil","title":null,"shares":100,"price_per_share":188.57,"usd_value":18857,"security_title":"Common Stock","importance":35.018857},{"ts":"2026-06-29","kind":"sec.filing","form_type":"144","title":"144 — Revolution Medicines, Inc. — 2026-06-29","url_slug":"/sec/cik-0001628171/144/0001950047-26-006611","accession_number":"0001950047-26-006611","importance":30},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Patel Sushil","title":null,"shares":2955,"price_per_share":37.54,"usd_value":110931,"security_title":"Common Stock","importance":15.1109307},{"ts":"2026-06-26","kind":"sec.filing","form_type":"4","title":"4 — Revolution Medicines, Inc. — 2026-06-26","url_slug":"/sec/cik-0001628171/4/0001610717-26-000296","accession_number":"0001610717-26-000296","importance":30},{"ts":"2026-06-24","kind":"sec.form144","reporter":"JACK ANDERS","title":"Officer","shares":20000,"usd_value":3390200,"security_title":"Common","approx_sale_date":"2026-06-24","accession_number":"0001950047-26-006461","importance":40.67804},{"ts":"2026-06-24","kind":"sec.insider.s","reporter":"Anders Jack","title":"Chief Financial Officer","shares":9496,"price_per_share":168.1959,"usd_value":1597188,"security_title":"Common Stock","importance":36.597188266399996},{"ts":"2026-06-24","kind":"sec.insider.s","reporter":"Anders Jack","title":"Chief Financial Officer","shares":5651,"price_per_share":169.2441,"usd_value":956398,"security_title":"Common Stock","importance":35.9563984091},{"ts":"2026-06-24","kind":"sec.insider.s","reporter":"Anders Jack","title":"Chief Financial Officer","shares":4553,"price_per_share":167.345,"usd_value":761922,"security_title":"Common Stock","importance":35.761921785},{"ts":"2026-06-24","kind":"sec.insider.s","reporter":"Anders Jack","title":"Chief Financial Officer","shares":300,"price_per_share":170.32,"usd_value":51096,"security_title":"Common Stock","importance":35.051096},{"ts":"2026-06-24","kind":"sec.filing","form_type":"144","title":"144 — Revolution Medicines, Inc. — 2026-06-24","url_slug":"/sec/cik-0001628171/144/0001950047-26-006461","accession_number":"0001950047-26-006461","importance":30},{"ts":"2026-06-24","kind":"sec.insider.m","reporter":"Anders Jack","title":"Chief Financial Officer","shares":20000,"price_per_share":18.56,"usd_value":371200,"security_title":"Common Stock","importance":15.3712},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — Revolution Medicines, Inc. — 2026-06-23","url_slug":"/sec/cik-0001628171/4/0001610717-26-000281","accession_number":"0001610717-26-000281","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — Revolution Medicines, Inc. — 2026-06-23","url_slug":"/sec/cik-0001628171/4/0001610717-26-000284","accession_number":"0001610717-26-000284","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — Revolution Medicines, Inc. — 2026-06-23","url_slug":"/sec/cik-0001628171/4/0001610717-26-000285","accession_number":"0001610717-26-000285","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — Revolution Medicines, Inc. — 2026-06-23","url_slug":"/sec/cik-0001628171/4/0001610717-26-000286","accession_number":"0001610717-26-000286","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — Revolution Medicines, Inc. — 2026-06-23","url_slug":"/sec/cik-0001628171/4/0001610717-26-000287","accession_number":"0001610717-26-000287","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — Revolution Medicines, Inc. — 2026-06-23","url_slug":"/sec/cik-0001628171/4/0001610717-26-000290","accession_number":"0001610717-26-000290","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"8-K","title":"8-K — Revolution Medicines, Inc. — 2026-06-22","url_slug":"/sec/cik-0001628171/8-k/0001193125-26-276718","accession_number":"0001193125-26-276718","importance":35},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — Revolution Medicines, Inc. — 2026-06-18","url_slug":"/sec/cik-0001628171/4/0001610717-26-000244","accession_number":"0001610717-26-000244","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — Revolution Medicines, Inc. — 2026-06-18","url_slug":"/sec/cik-0001628171/4/0001610717-26-000245","accession_number":"0001610717-26-000245","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — Revolution Medicines, Inc. — 2026-06-18","url_slug":"/sec/cik-0001628171/4/0001610717-26-000247","accession_number":"0001610717-26-000247","importance":30},{"ts":"2026-06-18","kind":"sec.insider.a","reporter":"Borisy Alexis","title":null,"shares":1191,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.a","reporter":"Borellini Flavia","title":null,"shares":1191,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.a","reporter":"Patel Sushil","title":null,"shares":1191,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.a","reporter":"Horning Sandra","title":null,"shares":1191,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.a","reporter":"Clyburn Frank","title":null,"shares":1191,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.a","reporter":"ANDERSON ELIZABETH M","title":null,"shares":1191,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.a","reporter":"Kim Lorence H.","title":null,"shares":1191,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":29600,"price_per_share":160.1243,"usd_value":4739679,"security_title":"Common Stock","importance":39.73967928},{"ts":"2026-06-17","kind":"sec.insider.m","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":25725,"price_per_share":26.5,"usd_value":681713,"security_title":"Common Stock","importance":15.6817125},{"ts":"2026-06-17","kind":"sec.insider.m","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":3302,"price_per_share":29.8,"usd_value":98400,"security_title":"Common Stock","importance":15.0983996},{"ts":"2026-06-17","kind":"sec.insider.m","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":573,"price_per_share":40.74,"usd_value":23344,"security_title":"Common Stock","importance":15.02334402},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"GOLDSMITH MARK A","title":"See Remarks","shares":10020,"price_per_share":156.1188,"usd_value":1564310,"security_title":"Common Stock","importance":36.564310376},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"Mancini Anthony","title":"See Remarks","shares":4615,"price_per_share":156.1192,"usd_value":720490,"security_title":"Common Stock","importance":35.720490108},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"Kelsey Stephen Michael","title":"See Remarks","shares":4175,"price_per_share":156.1192,"usd_value":651798,"security_title":"Common Stock","importance":35.65179766},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"Anders Jack","title":"Chief Financial Officer","shares":2722,"price_per_share":156.1192,"usd_value":424956,"security_title":"Common Stock","importance":35.4249564624},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"Cislini Jeff","title":"General Counsel","shares":2157,"price_per_share":156.1191,"usd_value":336749,"security_title":"Common Stock","importance":35.3367488987},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":60400,"price_per_share":160.1706,"usd_value":9674304,"security_title":"Common Stock","importance":44.67430424},{"ts":"2026-06-15","kind":"sec.form144","reporter":"MARGARET A HORN","title":"Officer","shares":90000,"usd_value":13848300,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001950047-26-006148","importance":42.76966},{"ts":"2026-06-15","kind":"sec.form144","reporter":"GOLDSMITH MARK A","title":"Officer, Director","shares":9772,"usd_value":1503618,"security_title":"Common Stock","approx_sale_date":"2026-06-15","accession_number":"0001246842-26-000002","importance":40.300723528},{"ts":"2026-06-15","kind":"sec.form144","reporter":"Mancini Anthony","title":"Officer","shares":4211,"usd_value":647947,"security_title":"Common Stock","approx_sale_date":"2026-06-15","accession_number":"0002124509-26-000003","importance":40.129589314},{"ts":"2026-06-15","kind":"sec.form144","reporter":"Kelsey Stephen Michael","title":"Officer","shares":4071,"usd_value":626405,"security_title":"Common Stock","approx_sale_date":"2026-06-15","accession_number":"0001462808-26-000002","importance":40.125280954},{"ts":"2026-06-15","kind":"sec.form144","reporter":"Horn Margaret A","title":"Officer","shares":3486,"usd_value":536391,"security_title":"Common Stock","approx_sale_date":"2026-06-15","accession_number":"0001294192-26-000002","importance":40.107278164},{"ts":"2026-06-15","kind":"sec.form144","reporter":"Anders Jack","title":"Officer","shares":2653,"usd_value":408217,"security_title":"Common Stock","approx_sale_date":"2026-06-15","accession_number":"0001800668-26-000002","importance":40.081643422},{"ts":"2026-06-15","kind":"sec.form144","reporter":"Cislini Jeff","title":"Officer","shares":1656,"usd_value":254809,"security_title":"Common Stock","approx_sale_date":"2026-06-15","accession_number":"0001969082-26-000004","importance":40.050961744},{"ts":"2026-06-15","kind":"sec.filing","form_type":"144","title":"144 — Revolution Medicines, Inc. — 2026-06-15","url_slug":"/sec/cik-0001628171/144/0001800668-26-000002","accession_number":"0001800668-26-000002","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"144","title":"144 — Revolution Medicines, Inc. — 2026-06-15","url_slug":"/sec/cik-0001628171/144/0001969082-26-000004","accession_number":"0001969082-26-000004","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"144","title":"144 — Revolution Medicines, Inc. — 2026-06-15","url_slug":"/sec/cik-0001628171/144/0002124509-26-000003","accession_number":"0002124509-26-000003","importance":30},{"ts":"2026-06-15","kind":"sec.insider.m","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":44854,"price_per_share":29.8,"usd_value":1336649,"security_title":"Common Stock","importance":16.3366492},{"ts":"2026-06-15","kind":"sec.insider.m","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":15546,"price_per_share":40.74,"usd_value":633344,"security_title":"Common Stock","importance":15.63334404},{"ts":"2026-06-11","kind":"sec.form144","reporter":"MARGARET A HORN","title":"Officer","shares":10000,"usd_value":1441900,"security_title":"Common","approx_sale_date":"2026-06-11","accession_number":"0001950047-26-005947","importance":40.28838},{"ts":"2026-06-11","kind":"sec.insider.s","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":4600,"price_per_share":149.6429,"usd_value":688357,"security_title":"Common Stock","importance":35.68835734},{"ts":"2026-06-11","kind":"sec.insider.s","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":1800,"price_per_share":148.7231,"usd_value":267702,"security_title":"Common Stock","importance":35.26770158},{"ts":"2026-06-11","kind":"sec.insider.s","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":1315,"price_per_share":144.2793,"usd_value":189727,"security_title":"Common Stock","importance":35.1897272795},{"ts":"2026-06-11","kind":"sec.insider.s","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":885,"price_per_share":145.1495,"usd_value":128457,"security_title":"Common Stock","importance":35.1284573075},{"ts":"2026-06-11","kind":"sec.insider.s","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":700,"price_per_share":146.0371,"usd_value":102226,"security_title":"Common Stock","importance":35.10222597},{"ts":"2026-06-11","kind":"sec.insider.s","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":500,"price_per_share":147.272,"usd_value":73636,"security_title":"Common Stock","importance":35.073636},{"ts":"2026-06-11","kind":"sec.insider.s","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":200,"price_per_share":150.17,"usd_value":30034,"security_title":"Common Stock","importance":35.030034},{"ts":"2026-06-11","kind":"sec.insider.m","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":8906,"price_per_share":40.74,"usd_value":362830,"security_title":"Common Stock","importance":15.36283044},{"ts":"2026-06-11","kind":"sec.insider.m","reporter":"Horn Margaret A","title":"Chief Operating Officer","shares":1094,"price_per_share":42.45,"usd_value":46440,"security_title":"Common Stock","importance":15.0464403},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Revolution Medicines, Inc.","title":"Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05462717","excerpt":"[\"Non-Small Cell Lung Cancer (NSCLC)\",\"Colorectal Cancer (CRC)\",\"Pancreatic Ductal Adenocarcinoma\",\"Advanced Solid Tumor\"]","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"Revolution Medicines, Inc.","title":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07397338","excerpt":"[\"Advanced Solid Tumors\",\"Metastatic Solid Tumors\",\"Non-small Cell Lung Cancer (NSCLC)\",\"NSCLC\",\"Colorectal Cancer (CRC)\",\"CRC\"]","importance":45},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Revolution Medicines, Inc.","title":"Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma","security_title":null,"status":"AVAILABLE","accession_number":"NCT07573215","excerpt":"[\"PDAC\",\"PDAC - Pancreatic Ductal Adenocarcinoma\",\"Metastatic Pancreas Adenocarcinoma\",\"Pancreatic Cancer\",\"Pancreatic Cancer Metastatic\",\"Pancreatic Adenocarcinoma Metastatic\",\"Pancreatic Adenocarcinoma\",\"Pancreatic Adenosquamous Carcinoma\"]","importance":25},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Revolution Medicines, Inc.","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06625320","excerpt":"[\"Pancreatic Cancer\",\"PDAC\",\"PDAC - Pancreatic Ductal Adenocarcinoma\"]","importance":60},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Revolution Medicines, Inc. — 2026-04-27","url_slug":"/sec/cik-0001628171/def-14a/0001193125-26-182453","accession_number":"0001193125-26-182453","importance":40},{"ts":"2026-04-27","kind":"sec.filing","form_type":"144","title":"144 — Revolution Medicines, Inc. — 2026-04-27","url_slug":"/sec/cik-0001628171/144/0001950047-26-003774","accession_number":"0001950047-26-003774","importance":30},{"ts":"2026-04-01","kind":"clinical.trial","reporter":"Revolution Medicines, Inc.","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06445062","excerpt":"[\"Colorectal Cancer\",\"CRC\",\"Pancreatic Ductal Adenocarcinoma\",\"PDAC\",\"Gastrointestinal Cancer\",\"Metastatic Pancreatic Ductal Adenocarcinoma\"]","importance":45}]}